Related Experiment Video
Updated: Dec 19, 2025

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
CXCL4 suppresses tolerogenic immune signature of monocyte-derived dendritic cells
Sandra C Silva-Cardoso1,2, Weiyang Tao1,2, Beatriz Malvar Fernández1,2
1Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract:
RNA sequencing and DNA methylomic profiling were performed after differentiating monocytes for 6 days into moDCs with/without CXCL4 presence. We show that CXCL4 downregulates genes associated with tolerogenicity in DCs including C1Q. Expression profiles of C1Q genes were negatively correlated with their DNA methylation profiles and with immunogenic genes.
Insights
CXCL4 reduces tolerogenic gene expression in monocyte-derived dendritic cells (moDCs), including C1Q. This downregulation correlates with increased DNA methylation and immunogenic gene activity.
Area of Science:
- Immunology
- Molecular Biology
- Epigenetics
Background:
- Monocytes are differentiated into monocyte-derived dendritic cells (moDCs) over six days.
- The role of chemokine CXCL4 in modulating moDC function and gene expression was investigated.
- RNA sequencing and DNA methylomic profiling were employed to analyze gene expression and epigenetic modifications.
Discussion:
- CXCL4 significantly downregulates genes critical for dendritic cell (DC) tolerogenicity, notably C1Q.
- Gene expression levels of C1Q were found to be inversely correlated with DNA methylation patterns.
- The presence of CXCL4 appears to promote a more immunogenic profile in moDCs.
Key Insights:
- CXCL4 acts as a negative regulator of tolerogenic pathways in moDCs.
- Epigenetic modifications, specifically DNA methylation, are linked to CXCL4-mediated gene silencing.
- C1Q gene expression is a key target of CXCL4's immunomodulatory effects.
Outlook:
- Further research into the precise mechanisms of CXCL4-induced epigenetic changes in DCs.
- Exploring the therapeutic potential of targeting the CXCL4-DC axis in immune-related diseases.
- Investigating the broader impact of CXCL4 on immune cell differentiation and function.

